New drug combo aims to control rare ovarian cancer
NCT ID NCT06065462
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining two drugs, dostarlimab and LB-100, can help control ovarian clear cell carcinoma. About 21 adults with recurrent disease will receive the drugs by vein. The main goal is to check safety and see if the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dostarlimab and LB-100
- What this could lead to
- If it works, this combination could offer a new treatment option for ovarian clear cell carcinoma, helping to control the disease.
- What could go wrong
- This is an early phase 1/2 trial with only 21 participants, so results are preliminary. The drugs may cause side effects and may not effectively control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CLEAR CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill target Hard-to-Treat ovarian cancers?
- Can a smart drug missile take down a tough ovarian cancer?
- New pill aims to shrink Hard-to-Treat cancers
- New drug duo aims to outperform chemo in rare ovarian cancer
- New targeted drug shows promise for Hard-to-Treat gynecologic cancers
- New drug aims to reactivate Cancer-Fighting genes in solid tumors